Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in South Korea / NCT06903845
Recruiting Not applicable

APIXABAN App Study

NCT06903845 · tracked via the Priya Life Science South Korea tracker
Sponsor
Dong-Ju Choi
Phase
Not applicable
Started
2025-03-01
Last updated
2025-04-06

Condition(s) studied

Atrial Fibrillation

Investigational drug(s) / intervention(s)

video callMedication reminder app

video call: Conduct video training every two weeks emphasizing medication adherence.

Medication reminder app: Medication reminder app will remind patients to take your medication.

Study summary

The aim of this clinical trial is to evaluate whether the medication reminder app and video call can improve medication adherence to apixaban in patients with AF and comorbidities.

Patients with AF and comorbid heart disease taking apixaban who meet the inclusion criteria will be randomised 1:1 to a treatment arm using a medication reminder app and bi-weekly video education and a control arm using the medication reminder app alone to compare medication adherence.

Patients in both groups will use the medication app, but only the treatment group will receive additional education and feedback via video call every two weeks to reinforce the use of the medication app and medication reminders with video education.

The study aims to assess the change in adherence between the two groups at week 8.

Eligibility

Sex
ALL
Min age
19 Years
Max age
—
Healthy volunteers
No
Participants must meet all of the following criteria: Adults aged 19 years or older with a diagnosis of atrial fibrillation (AF) Presence of at least one of the following cardiovascular or metabolic comorbidities: A. Heart failure B. Hypertension C. Coronary artery disease D. Peripheral arterial disease E. Diabetes mellitus F. Stroke G. Other cardiac diseases requiring treatment Currently taking or planning to initiate oral anticoagulation therapy with apixaban Able to use a smartphone with an Android operating system Voluntarily provided written informed consent to participate in the clinical trial after being adequately informed of its purpose, procedures, and potential risks 2\. Exclusion Criteria Participants will be excluded if any of the following conditions apply: Creatinine clearance (CCr) \< 15 mL/min Presence of moderate to severe mitral stenosis History of mitral valve repair or replacement Clinically significant history of alcohol or substance abuse Deemed by the investigator to be legally or psychologically unsuitable for participation in the clinical trial Participation in another clinical trial involving investigational drugs within 4 weeks prior to screening Declines or is unwilling to provide informed consent for participation in this study

Primary outcome measure(s)

  • Medication adherence by pill count — From enrollment to the end of treatment at 8 weeks
    Medication adherence by pill count: both the value itself and the percentage of 100% achieved

Trial sites (1)

FacilityCityRegionStatus
Seoul National University Bundang Hospital Seongnam Gyeonggido Recruiting

Other trials for the same condition

Thickness Map-Guided vs. Empirical PV Isolation Using Pulsed Field Ablation for Paroxysmal AF Starting soon
The Evaluation for Prognostic Factors After Catheter Ablation of Atrial Fibrillation: Cohort Study Recruiting
Evaluation of a Single-lead ECG Patch-based Telemetry System for In-hospital Monitoring Starting soon
PULSED AF Post-Approval Study Recruiting
To Compare and Evaluate the Efficacy and Safety Between TS-RF System and BRK Transseptal Needles Used for Transseptal Puncture for Left Atrial Access. Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06903845 on ClinicalTrials.gov ↗ ← All trials in South Korea